Given these limitations, future research should prioritize expanding the patient cohort, incorporating a wider range of clinical and biochemical parameters, and delving deeper into the mechanistic pathways of FOXM1 in HCC. The gene discussed is FOXM1; the disease is hepatocellular carcinoma.